D. Keith Grossman, chairman, CEO and president of Nevro Corporation, discusses the Company, expanding indications and driving growth through innovation and evidence in an interview with SmartTRAK

Nevro’s Keith Grossman expects randomized controlled trials and recent FDA approvals for expanded indications--painful diabetic neuropathy (PDN) and non-surgical refractory back pain (NSRBP)--to provide a competitive edge and help drive growth in the market for spinal cord stimulation (SCS). To find out more, including Grossman’s take on Medtronic’s recent FDA approval for the diabetic peripheral neuropathy (DPN) indication, click on the following video recorded live* via Google Meet (40:20 min). Specific interview topics by time code are also outlined below. If you would like to download a complete transcript of the interview, please click here.

A big boost in Q2 with double-digit gains in all segments.

The US and WW SCS Market boomeranged to pre-COVID levels in Q221 driven by declining COVID-19 cases and ongoing launches of new technologies and products. With easy comps against a quarter that was one of the hardest hit by the pandemic in 2020, Q221 growth was up in the double digits vs Q220 and was up in the low-single digits compared to Q219.

Among the many topics covered in detail in our comprehensive Q221 SCS Market Recap* are:

Brett Wall, EVP and President of Medtronic’s Neuroscience Portfolio, discusses changes and opportunities in the Neuroscience business in an interview with SmartTRAK. 

Brett Wall, EVP and President of Medtronic’s Neuroscience Portfolio, discusses how things are changing at Medtronic, his plans for the Neuroscience business and opportunities for growth in an interview with SmartTRAK. To find out more, including Wall’s vision for spine, neuromodulation and neurovascular, click on the following video. (25:58 min). A link to download a complete transcript of the interview is also provided below.

SNIS President William J. Mack, MD discusses trends and technologies in stroke care in an interview with SmartTRAK

• Advancing the stroke systems of care
• Trends in practice and device use for acute ischemic stroke
• Risks, benefits and challenges of treating more distal strokes
• Promising technologies on the horizon, including robotics
• Impact of COVID resurgence on clinical practice

To get the latest on stroke care, click on the following video to listen to a fascinating interview recorded live at SNIS (13:08). A link to download a transcript of the complete interview is also provided below.

As in-person meetings start to ramp up in 2021, SmartTRAK identifies the latest research, technologies and trends from ASPN and the mid-year NANS meetings

In this article, SmartTRAK identifies the latest research, technologies and trends at two recent neuromodulation meetings: the mid-year North American Neuromodulation Society (NANS) 2021 meeting, held July 15-18 in Orlando, FL and the American Society of Pain and Neuroscience (ASPN) meeting held in Miami, FL July 22-25. Following are the highlights of the neuromodulation news from these meetings in the areas of expanding indications, digital solutions and peripheral nerve stimulation (PNS) as covered by Anne Staylor, SmartTRAK's Executive Editor, VP & GM, Nuero Therapies.

To read this fascinating and informative article in it's entirety, you must be a subscriber to SmartTRAK...here's how to subscribe.

• SCS for Painful Diabetic Neuropathy
  • In regards to expanded indications, the biggest news during the mid-year NANS meeting happened on Friday, July 16th when FDA approved Nevro’s* (NVRO) HF10 for ... 
• Non-Surgical Refractory Back Pain.
  • During NVRO’s industry luncheon, Aaron Calodney, MD presented six-month data on 10 kHz SCS for non-surgical refractory back pain (NSRBP) vs CMM ...
• Advances in Digital Solutions
  • All the major players in neuromodulation continue to advance patient care through innovative digital solutions and platforms designed to improve patient engagement and outcomes, track objective pain measures and ...

RapidAI President and CEO Don Listwin discusses how advances in AI-based imaging, workflow and products are improving stroke care in an interview with SmartTRAK

RapidAI, the market leader in brain imaging analysis, processed more than 1MM stroke imaging scans in 2020 alone, up 100% year-over-year, despite COVID-19. Using AI-based software and decision support tools, the Company is helping stroke professionals identify and diagnose more cerebrovascular disorders than ever before, driving double-digit growth in stroke procedures for some hospitals. Although challenges remain in getting the right patient to the right hospital in a timely fashion, RapidAI is working to improve outcomes and the stroke systems of care through improved workflow and messaging technologies, AI-based analytics and new products, such as non-contrast scans that will improve decision-making at some of the smaller spoke hospitals and prevent unnecessary transfers to comprehensive stroke centers.

To find out more, including RapidAI’s plans for indications outside of stroke care, SmartTRAK interviewed RapidAI President and CEO Don Listwin. To listen to the interview, recorded via Uberconference, click on the following video (25:40 min). A link to download a transcript of the interview is also provided below.

In an interview with SmartTRAK, André Mercanzini, founder and CEO of Aleva Neurotherapeutics, discusses the Company's next-gen DBS System and improving outcomes via miniaturization and MEMS-based technologies.

Despite a resurgence in COVID-19 that impacted procedure volumes early in Q121, the SCS Market’s climb to pre-pandemic levels is well underway.

Although a resurgence in COVID-19 in late 2020 negatively affected procedure volumes early in the quarter, the SCS Market’s climb to pre-pandemic levels has started to gain momentum. For Q121, US SCS revenues were up +13.6% YoY while WW SCS revenues also saw double-digit YoY growth according to SmartTRAK Financial Dashboard.

Among the many topics covered in detail in our comprehensive Q121 SCS Market Recap* are:

Dan Volz, President of Medtronic Neurovascular, discusses what’s next for Medtronic Neurovascular in an interview with SmartTRAK.

Aure Bruneau, CEO of Stimwave, discusses his vision for the Company and taking peripheral nerve stimulation to the next level in an interview with SmartTRAK

Since starting as CEO of Stimwave in April 2020, Aure Bruneau has brought a new vision, energy and focus to the Company.  In the last 12 months, the former Zimmer Biomet executive has been positioning Stimwave for growth, building a high performing team and rebuilding the foundation of the Company, touching almost every aspect of the business, including regulatory, quality, manufacturing operations, marketing, IT, compliance and R&D. Strategically, Bruneau has refined the Company’s spinal cord stimulation (SCS) strategy and shifted efforts toward peripheral nerve stimulation (PNS) where he believes the technology will have a more meaningful impact and a market opportunity as big as the existing SCS market. In fact, he estimates the PNS opportunity to be at least $1.5 billion to treat chronic pain just for selected musculoskeletal indications (shoulders, knees, feet, ankles and the SI joint).

Looking ahead, Stimwave is planning to launch new products and a series of clinical trials in 2021 to validate a new standard of care that will help take the Company’s PNS platform to the next level and help drive future growth.

To find out more, click on the following video (26:35 min) and listen to SmartTRAK’s interview with Bruneau recorded recently via Uberconference. A transcript of the complete interview is also available below.